Syndax Pharmaceuticals, Inc. (SNDX) News
Track canonical SquawkNews coverage tagged to SNDX, Syndax Pharmaceuticals, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 11 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
SNDX: Key phase II readouts and expanding maintenance therapy drive growth and pipeline momentum
Two commercial drugs are driving strong revenue growth, with recurring post-transplant maintenance therapy emerging as a key driver. Multiple pivotal and phase II readouts are expected in the next year, including for IPF
EARNINGS | Sep 15, 2026, 03:24 PM UTC
L
SNDX: Strong commercial growth and pivotal clinical catalysts set the stage for major pipeline advances
Two commercial assets are driving strong revenue growth, with real-world data supporting expanded use and maintenance therapy as a key growth driver. Multiple near-term clinical readouts, including for IPF and cGVHD, and
NEWS | Sep 15, 2026, 02:53 PM UTC
L
SNDX: Dominant AML market share, advancing pivotal trials, and expanding pipeline in oncology and fibrosis
Strong commercial momentum continues with 85%+ AML market share and robust revenue growth. Multiple pivotal and innovative studies are advancing in AML, IPF, and GVHD, with key data readouts expected by year-end. Early-s
EQUITY | Sep 10, 2026, 02:21 PM UTC
L
SNDX: Dominant AML market share, global pivotal trials, and major data readouts expected in Q4 and at ASH
Strong commercial momentum continues with 85%+ market share in key AML segments and robust growth. Two pivotal phase III AML studies are enrolling globally, with additional innovation in IPF, GVHD, and novel oncology pro
EQUITY | Sep 10, 2026, 01:41 PM UTC
L
Syndax Pharmaceuticals grants inducement awards for up to 175,000 shares
Syndax Pharmaceuticals announced inducement grants under NASDAQ Listing Rule 5635(c)(4) on Sept. 1, 2026, to purchase up to 175,000 shares of common stock.
EQUITY | Sep 04, 2026, 08:07 PM UTC
L
Syndax Pharmaceuticals reports inducement grants under NASDAQ Rule 5635(c)(4)
Syndax Pharmaceuticals (SNDX) reports inducement grants under NASDAQ Listing Rule 5635(c)(4).
EQUITY | Sep 04, 2026, 08:01 PM UTC
L
Syndax management to participate in September investor conferences
Syndax Pharmaceuticals said CEO Michael A. Metzger and members of the management team will participate in September investor conferences.
EQUITY | Sep 01, 2026, 11:08 AM UTC
L
Syndax to participate in September investor conferences
Syndax says it will participate in September investor conferences.
EQUITY | Sep 01, 2026, 11:00 AM UTC
L
SNDX - Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
SNDX - Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
EARNINGS | Aug 04, 2026, 08:02 PM UTC
L
SNDX Maintain Buy, $31 PT following R&D day @ GUGG
SNDX Maintain Buy, $31 PT following R&D day @ GUGG
EQUITY | Jul 15, 2026, 12:56 PM UTC
L
Syndax Pharmaceuticals Insider Sold Shares Worth $784,776, According to a Recent SEC Filing
() -- Michael A Metzger, Director, Chief Executive Officer, on July 08, 2026, sold 32,375 shares in Syndax Pharmaceuticals (SNDX) for $784,776. Following the Form 4 filing with the SEC, Metzger has control over a total o
REGULATION | Jul 09, 2026, 08:57 PM UTC